Bio News
Argenx will acquire Forte Biosciences for $2.2 billion, or approximately 3.3 trillion won, securing a Phase 2 vitiligo treatment. The acquired drug candidate, FB102, is an anti-CD122 antibody that recently improved facial vitiligo scores by 29.6% in a Phase 1b trial. Argenx will acquire Forte shares for $77 per share, a 40.5% premium, and plans to expand the drug’s indications to celiac disease and alopecia areata.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
